FDA has approved Zealand Pharma's Investigative New Drug application for ZP1846 to be administered in humans(09/10/2007) ZP1846 developed for the prevention and treatment of severe diarrhoea induced by chemotherapy Zealand Pharma advances ZP1846 into Phase I clinical trials. ZP1846, a peptide which incorporates Zealand's proprietary SIP technology, is developed as a therapy for the prevention and treatment of chemotherapy-induced diarrhoea, a debilitating ...
Top
